Pricing Log in Create free account
Friday 6 November 2026 Export TELA’s income statement to Excel — free account

TELA Bio, Inc.

TELA Healthcare Medical Devices

TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024.

Revenue
−4.49%
EPS
+9.09%
Free cash flow
−17.7%
Total debt
+35.5%

Quarter to June 2026, against a year earlier

0.81 0.03 +3.85%
Market cap
$35.2M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
3/9
Altman Z
−5.93
Beneish M
−3.31
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.19
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — 2 2 — —
Sell — — — — — — — — — — — —
Insider Ownership 41.81%

Capital & Financial Ratios $m

Size
Market Cap 35.21
Revenue ttm 79.91
Net income ttm (41.18)
Free cash flow ttm (31.62)
Net debt Q 25.66
Valuation
P/E 0.00
Forward P/E (1.16) (negative: loss-making)
Price / sales 0.60
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 2.99 (at or above 1.5: strong)
Debt / equity Q (3.53) (negative: negative equity)
Interest coverage Q (4.47)
Growth
Revenue growth Q −4.49% (below 0%: shrinking)
Operating income growth Q −2.22% (below 0%: shrinking)
EPS, this year +16.97% (at or above 15%: strong)
EPS, next year A +35.67% (at or above 15%: strong)
Revenue, next year A −0.97% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +26.12% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.0×, against a ten-year median of 3.2×; over the ten years it ranged from 0.0× in 2019 to 10.8× in 2020.
P/S against its own 10 years 10.02%
10-year low 10-year high
EV/Sales against its own 10 years 19.64%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 47 53 51 30
Receivables 10 10 10 10
Inventory 13 13 11 11
Other — — — —
72 78 76 54
2023 2024 2025 Q'26
Payables 2 2 2 3
ST’ Debt — — — —
Other — — — —
17 16 18 18

Compound Annual Growth %

10y 5y 3y
Sales — 34.54% 24.68%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (33.63%) (23.87%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.17 Actual −0.20

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.17 −0.19 Miss by 0.02
Q4 FY25 −0.18 −0.16 Beat by 0.02
Q1 FY26 −0.14 −0.21 Miss by 0.07
Q2 FY26 −0.17 −0.20 Miss by 0.03
Q3 FY26 −0.19 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.21) (0.20) — — —
’25 (0.25) (0.22) (0.19) (0.17) (0.83)
’24 (0.23) (0.51) (0.42) (0.23) (1.33)
’23 (0.63) (0.46) (0.45) (0.53) (2.04)
’22 (0.75) (0.88) (0.64) (0.52) (2.72)
’21 (0.56) (0.57) (0.57) (0.59) (2.30)
’20 (0.63) (0.53) (0.53) (0.54) (2.23)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 19 19 — — —
’25 19 20 21 21 80
’24 17 16 19 18 69
’23 12 14 15 17 58
’22 8 10 11 12 41
’21 6 8 8 8 29
’20 4 4 5 6 18
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (11) (9) — — —
’25 (10) (8) (6) (5) (28)
’24 (14) (11) (9) (8) (42)
’23 (12) (11) (7) (11) (41)
’22 (10) (12) (8) (11) (41)
’21 (9) (6) (7) (10) (30)
’20 (7) (6) (4) (7) (24)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (11) (9) — — —
’25 (10) (8) (6) (5) (29)
’24 (15) (11) (9) (8) (43)
’23 (12) (11) (7) (11) (41)
’22 (11) (12) (8) (12) (43)
’21 (9) (6) (7) (10) (31)
’20 (7) (6) (4) (7) (25)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 4 8 15 18 29 41 58 69 80 80 +44.4% 80 86 96 +6.2%
Gross margin, % — 59.65 45.04 62.00 63.35 64.88 67.24 69.27 67.63 68.17 68.29 +8.5 pt
EBT — (21) (21) (22) (29) (33) (44) (47) (38) (39) (41) +7.7%
EBT margin, % — (502.57) (254.92) (145.18) (158.10) (112.94) (106.95) (79.83) (54.81) (48.09) (51.20) +454.5 pt
Net income — (21) (21) (22) (29) (33) (44) (47) (38) (39) (41) +7.8%
Per share, $
Per share, $ Revenue — 14.54 28.05 8.75 1.41 2.04 2.55 2.56 2.43 1.71 1.39 (23.5%)
Earnings — (93.25) (101.41) (17.10) (2.23) (2.30) (2.72) (2.04) (1.33) (0.83) (0.77) (44.6%)
Cash flow — (56.05) (67.54) (14.45) (1.89) (2.10) (2.50) (1.79) (1.46) (0.60) (0.54) (43.3%)
Capex — (0.35) (5.28) (1.53) (0.01) (0.04) (0.12) (0.03) (0.03) (0.01) (0.01) (36.2%)
Free cash flow — (56.40) (72.82) (15.98) (1.90) (2.15) (2.62) (1.81) (1.49) (0.61) (0.55) (43.2%)
Book value — (370.45) (467.32) 17.53 3.79 1.39 0.88 0.83 1.00 0.13 (0.28) n/m
Shares, m — 0 0 2 13 14 16 23 29 47 52 +88.7%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — 0.31 0.31 1.48 10.68 6.29 4.52 2.59 1.24 0.69 0.60 3.1
P/B — 0.00 0.00 0.74 3.97 9.22 13.08 8.02 3.03 8.78 0.00 5.2
EV/Sales — 1.90 1.90 (0.04) 8.34 5.90 4.47 2.49 1.08 0.79 0.97 3.0
EV/FCF — (0.91) (0.91) 0.02 (5.60) (5.18) (4.15) (3.27) (1.64) (2.01) (2.23) (2.6)
Cash, $m
Cash, $m Operating cash flow — (16) (20) (26) (24) (30) (41) (41) (42) (28) (31) +7.0%
Capex — 0 (2) (3) 0 (1) (2) (1) (1) 0 0 +20.5%
Free cash flow — (16) (21) (28) (25) (31) (43) (41) (43) (29) (32) +7.2%
Balance, $m
Balance, $m Working capital — 8 14 58 77 48 50 55 62 58 36 +27.6%
Net debt — (7) 12 (24) (44) (12) (2) (6) (12) 5 26 n/m
Shareholders’ equity — (108) (138) 31 49 20 14 19 28 6 (16) n/m
Returns, %
Returns, % ROA — (127.35) (139.92) (63.50) (37.30) (44.67) (67.94) (63.97) (45.97) (46.23) (64.71) +81.1 pt
ROIC — 0.00 0.00 (180.96) (289.37) (240.36) (199.80) (217.47) (126.08) (189.70) (217.11) (189.7) pt
ROE — 22.13 24.32 56.52 (72.00) (96.28) (257.51) (281.23) (159.87) (223.35) 1,232.54 (245.5) pt
People
People Employees — — 86 89 108 123 173 166 209 150 — +8.3%
Revenue/emp, $m — 0.00 0.10 0.17 0.17 0.24 0.24 0.35 0.33 0.54 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

TELA Bio, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MDAI Spectral AI, Inc. $44.4M — (loss-making) — (loss-making) −30.42% (below 0%: shrinking) n/m −21.86% (below 0%: shrinking) 31.58% (122.70%) Compare
XTNT Xtant Medical Holdings, Inc. $42.1M — (loss-making) — (loss-making) −34.96% (below 0%: shrinking) n/m −881.96% (below 0%: shrinking) 57.88% (39.81%) Compare
CVRX CVRx, Inc. $39.2M — (loss-making) — (loss-making) −5.84% (below 0%: shrinking) n/m −9.91% (below 0%: shrinking) 86.74% (94.31%) Compare
TELA TELA Bio, Inc. $35.2M — (loss-making) — (loss-making) −4.49% (below 0%: shrinking) n/m −17.72% (below 0%: shrinking) 72.77% (48.12%)
ELUT Elutia Inc. $33.3M 0.6× — (loss-making) −11.65% (below 0%: shrinking) n/m −2.52% (below 0%: shrinking) 59.62% (327.85%) Compare
RPID Rapid Micro Biosystems, Inc. $31.1M — (loss-making) — (loss-making) +10.91% (above 0%: growing) n/m −23.97% (below 0%: shrinking) 15.05% (152.99%) Compare
QTI QT Imaging Holdings, Inc. $30.3M — (loss-making) — (loss-making) +103.20% (above 0%: growing) n/m −236.31% (below 0%: shrinking) 41.16% (25.07%) Compare
NSYS Nortech Systems Incorporated $30.0M 28.4× 17.5× +9.34% (above 0%: growing) −8.33% (below 0%: shrinking) −1,567.16% (below 0%: shrinking) 17.00% 1.86% Compare
NSPR InspireMD, Inc. $29.7M — (loss-making) — (loss-making) −0.39% (below 0%: shrinking) n/m −26.00% (below 0%: shrinking) (43.70%) (815.64%) Compare
Median of peers $32.2M — — −3.11% — −24.99% 36.37% (108.50%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 14 September 2026

Ownership

Directors and executive officers, together 1.10%
Entities associated with EW Healthcare Partners, LLC 17.10%
Nantahala Capital Management, LLC 11.30%
Laurence W. Lytton 6.30%
North Run Capital, LP 5.90%
Stonepine Capital Management, LLC 5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

TELA Bio, Inc. (TELA) Latest News

27 Oct

Impact 3 · · GlobeNewswire

19 Oct

Impact 3 · · Simply Wall St.

5 Oct

Impact 4 · · GlobeNewswire

31 Aug

Impact 3 ·

19 Aug

Impact 4 · · The Motley Fool transcript

11 Aug

Impact 4 · · GlobeNewswire
Impact 3 · transcript
Impact 3 ·

10 Aug

Impact 3 · · Moby transcript
Impact 3 ·
Impact 3 ·

4 Aug

Impact 3 ·

15 May

Impact 3 · · Simply Wall St.

13 May

Impact 4 · · Moby
Impact 4 · · GuruFocus.com

12 May

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

30 Apr

Impact 4 · · GlobeNewswire

25 Mar

Impact 4 · · Moby

24 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · The Motley Fool transcript
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

14 Nov

Impact 4 · · GuruFocus.com

13 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks
Impact 3 · · GlobeNewswireGuruFocus.comMT NewswiresMT NewswiresMT Newswires

3 Nov

Impact 3 · · GlobeNewswire

9 Oct

Impact 3 · · Simply Wall St.

12 Aug

Impact 4 ·
stockrow.com/TELA · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com